Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Osteoarthritis, KneePain
Interventions
DRUG

V116517 50-mg tablets

Taken orally twice daily

DRUG

V116517 30-mg tablets

Taken orally twice daily

DRUG

Naproxen 500-mg capsules

Taken orally twice daily

DRUG

Placebo

Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily

Trial Locations (18)

16635

Altoona Center for Clinical Research, Duncansville

19610

Clinical Research Center of Reading, LLP, Wyomissing

27609

PMG Research of Raleigh, LLC, Raleigh

27612

Wake Research Associates, LLC, Raleigh

28209

PMG Research of Charlotte, LLC., Charlotte

32205

Westside Center for Clinical Research, Jacksonville

32216

Jacksonville Center for Clinical Research, Jacksonville

32720

Avail Clinical Research, LLC, DeLand

32765

Compass Research East, LLC, Oviedo

32806

Compass Research, LLC, Orlando

33458

Health Awareness, Inc., Jupiter

33472

Orthopedic Research Institute, Boynton Beach

37620

PMG Research of Bristol, Bristol

46383

Northwest Indiana Center for Clinical Research, Valparaiso

48706

Great Lakes Research Group, Inc., Bay City

73069

LION Research, Norman

85704

Genova Clinical Research, Inc., Tucson

01760

Analgesic Solutions, Natick

All Listed Sponsors
lead

Purdue Pharma LP

INDUSTRY

NCT01688934 - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee | Biotech Hunter | Biotech Hunter